Stine Bordier Høj1,2, Nanor Minoyan1,3, Andreea Adelina Artenie1,3, Jason Grebely4, Julie Bruneau1,2. 1. Research Centre of the Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, Québec, Canada. 2. Department of Family and Emergency Medicine, Université de Montréal, Montréal, Québec, Canada. 3. Department of Social and Preventive Medicine, Université de Montréal, Montréal, Québec, Canada. 4. The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
Abstract
Background: The worldwide economic, health, and social consequences of drug use disorders are devastating. Injection drug use is now a major factor contributing to hepatitis C virus (HCV) transmission globally, and it is an important public health concern. Methods: This article presents a narrative review of scientific evidence on public health strategies for HCV prevention among people who inject drugs (PWID) in Canada. Results: A combination of public health strategies including timely HCV detection and harm reduction (mostly needle and syringe programmes and opioid substitution therapy) have helped to reduce HCV transmission among PWID. The rising prevalence of pharmaceutical opioid and methamphetamine use and associated HCV risk in several Canadian settings has prompted further innovation in harm reduction, including supervised injection facilities and low-threshold opioid substitution therapies. Further significant decreases in HCV incidence and prevalence, and in corresponding disease burden, can only be accomplished by reducing transmission among high-risk persons and enhancing access to HCV treatment for those at the greatest risk of disease progression or viral transmission. Highly effective and tolerable direct-acting antiviral therapies have transformed the landscape for HCV-infected patients and are a valuable addition to the prevention toolkit. Curing HCV-infected persons, and thus eliminating new infections, is now a real possibility. Conclusions: Prevention strategies have not yet ended HCV transmission, and sharing of injecting equipment among PWID continues to challenge the World Health Organization goal of eliminating HCV as a global public health threat by 2030. Future needs for research, intervention implementation, and uptake in Canada are discussed.
Background: The worldwide economic, health, and social consequences of drug use disorders are devastating. Injection drug use is now a major factor contributing to hepatitis C virus (HCV) transmission globally, and it is an important public health concern. Methods: This article presents a narrative review of scientific evidence on public health strategies for HCV prevention among people who inject drugs (PWID) in Canada. Results: A combination of public health strategies including timely HCV detection and harm reduction (mostly needle and syringe programmes and opioid substitution therapy) have helped to reduce HCV transmission among PWID. The rising prevalence of pharmaceutical opioid and methamphetamine use and associated HCV risk in several Canadian settings has prompted further innovation in harm reduction, including supervised injection facilities and low-threshold opioid substitution therapies. Further significant decreases in HCV incidence and prevalence, and in corresponding disease burden, can only be accomplished by reducing transmission among high-risk persons and enhancing access to HCV treatment for those at the greatest risk of disease progression or viral transmission. Highly effective and tolerable direct-acting antiviral therapies have transformed the landscape for HCV-infected patients and are a valuable addition to the prevention toolkit. Curing HCV-infected persons, and thus eliminating new infections, is now a real possibility. Conclusions: Prevention strategies have not yet ended HCV transmission, and sharing of injecting equipment among PWID continues to challenge the World Health Organization goal of eliminating HCV as a global public health threat by 2030. Future needs for research, intervention implementation, and uptake in Canada are discussed.
Authors: Håvard Midgard; Behzad Hajarizadeh; Evan B Cunningham; Brian Conway; Markus Backmund; Philip Bruggmann; Julie Bruneau; Stefan Bourgeois; Adrian Dunlop; Graham R Foster; Margaret Hellard; Geert Robaeys; Maria C Thurnheer; Martin Weltman; Janaki Amin; Philippa S Marks; Sophie Quiene; Gregory J Dore; Olav Dalgard; Jason Grebely Journal: Int J Drug Policy Date: 2017-06-19
Authors: Evan Wood; Mark W Tyndall; Kathy Li; Elisa Lloyd-Smith; Will Small; Julio S G Montaner; Thomas Kerr Journal: Am J Prev Med Date: 2005-08 Impact factor: 5.043
Authors: M-J S Milloy; Jane Buxton; Evan Wood; Kathy Li; Julio S G Montaner; Thomas Kerr Journal: BMC Public Health Date: 2009-05-27 Impact factor: 3.295